Factors associated with the use of highly active antiretroviral therapy in patients newly entering care in an urban clinic

被引:95
作者
Giordano, TP
White, AC
Sajja, P
Graviss, EA
Arduino, RC
Adu-Oppong, A
Lahart, CJ
Visnegarwala, F
机构
[1] Baylor Coll Med, Infect Dis Sect, Houston, TX 77030 USA
[2] Baylor Coll Med, Sect Hlth Serv Res, Dept Med, Houston, TX 77030 USA
[3] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA
[4] Univ Texas, Hlth Sci Ctr, Sch Med, Dept Med,Sect Infect Dis, Houston, TX USA
关键词
highly active antiretroviral therapy; women; adherence; naive patients; appointments; HIV;
D O I
10.1097/00126334-200304010-00009
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Ethnic minority, female, and drug-using patients may be less likely to receive highly active antiretroviral therapy (HAART), despite its proven benefits. We reviewed the medical records of a consecutive population of 354 patients entering care in 1998 at the Thomas Street Clinic, an academically affiliated, public, HIV-specialty clinic in Houston, to determine the factors associated with not receiving HAART as recorded in pharmacy records. Ninety-two patients (26.0%) did not receive HAART during at least 6 months of follow-up. Patients who did not receive HAART were more likely to be women and to have missed more than two physician appointments and were less likely to have a CD4 count < 200 cells/muL or a viral load greater than or equal to 10(5) copies/mL. In multivariate logistic analysis, missed appointments (OR = 5.85, p < .0001), female sex (OR = 2.53, p = .001), and CD4 count greater than or equal to 200 cells/muL (OR = 2.50, p = .001) were independent predictors of not receiving HAART. More than half the patients who never received HAART never returned to the clinic after their first appointment. Among patients new to care, women and those with poor appointment adherence were less likely to receive HAART. Efforts to improve clinic retention and further study of the barriers to HAART use in women are needed.
引用
收藏
页码:399 / 405
页数:7
相关论文
共 40 条
[1]  
Andersen R, 2000, HEALTH SERV RES, V35, P389
[2]   Differential access in the receipt of antiretroviral drugs for the treatment of AIDS and its implications for survival [J].
Anderson, KH ;
Mitchell, JM .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (20) :3114-3120
[3]  
[Anonymous], HIV PREV STRAT PLAN
[4]   When should we delay highly active antiretroviral therapy? [J].
Bangsberg, DR ;
Moss, A .
JOURNAL OF GENERAL INTERNAL MEDICINE, 1999, 14 (07) :446-448
[5]  
Bassetti S, 1999, J ACQ IMMUN DEF SYND, V21, P114
[6]   Protease inhibitor use among a community sample of people with HIV disease [J].
Bing, EG ;
Kilbourne, AM ;
Brooks, RA ;
Lazarus, EF ;
Senak, M .
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 1999, 20 (05) :474-480
[7]   Clinical experience and choice of drug therapy for human immunodeficiency virus disease [J].
Brosgart, CL ;
Mitchell, TF ;
Coleman, RL ;
Dyner, T ;
Stephenson, KE ;
Abrams, DI .
CLINICAL INFECTIOUS DISEASES, 1999, 28 (01) :14-22
[8]  
CAPRIO M, 2002, 14 INT AIDS C BARC
[9]  
*CDCP, 1998, MMWR-MORBID MORTAL W, V47, P43
[10]   Time to initiating highly active antiretroviral therapy among HIV infected injection drug users [J].
Celentano, DD ;
Galai, N ;
Sethi, AK ;
Shah, NG ;
Strathdee, SA ;
Vlahov, D ;
Gallant, JE .
AIDS, 2001, 15 (13) :1707-1715